Effect of metabolic inhibitors on membrane immunofluorescence reactivity of established Burkitt lymphoma cell lines.
D000963:Antimetabolites / Q000494:pharmacology*; D001711:Biotransformation / Q000187:drug effects*; D002051:Burkitt Lymphoma / Q000276:immunology*; D002460:Cell Line / Q000187:drug effects / Q000528:radiation effects; D046508:Culture Techniques; D003561:Cytarabine / Q000494:pharmacology; D003609:Dactinomycin / Q000494:pharmacology; D005455:Fluorescent Antibody Technique; D006801:Humans; D008566:Membranes; D008727:Methotrexate / Q000494:pharmacology; D008937:Mitomycins / Q000494:pharmacology; D011691:Puromycin / Q000494:pharmacology
D000963:Antimetabolites; D008937:Mitomycins; D003561:Cytarabine; D003609:Dactinomycin; D011691:Puromycin; D008727:Methotrexate